Furiex Pharmaceuticals Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting

MORRISVILLE, N.C.--Oct. 31, 2011--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced its late-breaking abstract describing results from the Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, its investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome, was accepted for presentation at the upcoming American College of Gastroenterology Annual Scientific Meeting in Washington, DC. Dr. Charles Randall, clinical professor of medicine at the University of Texas Health Science Center of San Antonio and an investigator in this recently completed trial, will present the results at the Plenary Session 2, on November 1, 2011 at the Gaylord National Hotel and Convention Center in Washington, DC.

About MuDelta

MuDelta is a novel, orally active, Phase III-ready investigational agent with combined mu opioid receptor agonist and delta opioid receptor antagonist activity which acts locally in the gut and has very low oral bioavailability, diminishing sedating side effects. This dual opioid activity is designed to treat diarrhea and pain symptoms of IBS-D, without causing the constipating side effects that can occur with mu opioid agonists.

About IBS-D

Diarrhea-predominant irritable bowel syndrome is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 12 million Americans. Although the exact cause of IBS-D is not known, symptoms are thought to result from a disturbance in the way the gut and nervous system interact. IBS-D can be extremely debilitating and there are limited therapeutic options for managing the chronic symptoms. IBS-D is associated with economic burden in direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of internal and partnered drug programs by advancing them through the drug discovery and development process in a cost-efficient manner. Development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates including late-stage assets and two products on the market. The company’s mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.


Contacts
Furiex Pharmaceuticals, Inc.
Media/Analysts/Investors:
Sailash Patel, 919-456-7814
sailash.patel@furiex.com

 

Posted: October 2011

View comments

Hide
(web2)